CY1120260T1 - Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk - Google Patents
Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trkInfo
- Publication number
- CY1120260T1 CY1120260T1 CY20181100514T CY181100514T CY1120260T1 CY 1120260 T1 CY1120260 T1 CY 1120260T1 CY 20181100514 T CY20181100514 T CY 20181100514T CY 181100514 T CY181100514 T CY 181100514T CY 1120260 T1 CY1120260 T1 CY 1120260T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trk
- inhibitors
- pyrasol
- pyrimidine
- subjects
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 229940096912 Trk tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Ενώσεις του Τύπου (I), στον οποίο τα R1, R2, R3, R4, Χ, Υ και n έχουν τις σημασίες που δίδονται στην προδιαγραφή, είναι αναστολείς των κινασών Trk και είναι χρήσιμες στην θεραπευτική αντιμετώπιση ασθενειών, οι οποίες μπορεί να αντιμετωπιστούν θεραπευτικά με έναν αναστολέα κινάσης Trk.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10761608P | 2008-10-22 | 2008-10-22 | |
EP13197815.7A EP2725028B1 (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors |
EP09740245.7A EP2350071B1 (en) | 2008-10-22 | 2009-10-21 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120260T1 true CY1120260T1 (el) | 2019-07-10 |
Family
ID=41328903
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100831T CY1118199T1 (el) | 2008-10-22 | 2016-08-24 | Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk |
CY20181100514T CY1120260T1 (el) | 2008-10-22 | 2018-05-18 | Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk |
CY2020006C CY2020006I2 (el) | 2008-10-22 | 2020-03-16 | Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk |
CY20211101031T CY1124923T1 (el) | 2008-10-22 | 2021-11-26 | Υποκατεστημενες ενωσεις πυραζολο[1,5-α]πυριμιδινης ως αναστολεις κινασης trk |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100831T CY1118199T1 (el) | 2008-10-22 | 2016-08-24 | Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2020006C CY2020006I2 (el) | 2008-10-22 | 2020-03-16 | Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk |
CY20211101031T CY1124923T1 (el) | 2008-10-22 | 2021-11-26 | Υποκατεστημενες ενωσεις πυραζολο[1,5-α]πυριμιδινης ως αναστολεις κινασης trk |
Country Status (39)
Country | Link |
---|---|
US (11) | US8513263B2 (el) |
EP (4) | EP2725028B1 (el) |
JP (5) | JP5600111B2 (el) |
KR (5) | KR101652189B1 (el) |
CN (2) | CN102264736B (el) |
AR (2) | AR074052A1 (el) |
AU (1) | AU2009308465B2 (el) |
BR (1) | BRPI0919873B8 (el) |
CA (1) | CA2741313C (el) |
CL (1) | CL2011000880A1 (el) |
CO (1) | CO6440551A2 (el) |
CR (1) | CR20110261A (el) |
CY (4) | CY1118199T1 (el) |
DK (4) | DK3106463T6 (el) |
ES (4) | ES2588504T3 (el) |
HK (2) | HK1160640A1 (el) |
HR (3) | HRP20211722T1 (el) |
HU (4) | HUE057625T2 (el) |
IL (3) | IL212341A0 (el) |
LT (4) | LT3372605T (el) |
LU (1) | LUC00150I2 (el) |
ME (1) | ME03010B (el) |
MX (1) | MX2011004204A (el) |
MY (1) | MY169791A (el) |
NL (1) | NL301033I2 (el) |
NO (2) | NO3106463T3 (el) |
NZ (1) | NZ592809A (el) |
PL (4) | PL3106463T6 (el) |
PT (4) | PT3106463T (el) |
RS (3) | RS62869B1 (el) |
RU (2) | RU2523544C2 (el) |
SG (3) | SG196855A1 (el) |
SI (4) | SI3106463T1 (el) |
SM (1) | SMT201400153B (el) |
TR (1) | TR201807039T4 (el) |
TW (4) | TWI639605B (el) |
UA (1) | UA106054C2 (el) |
UY (1) | UY32192A (el) |
WO (1) | WO2010048314A1 (el) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103965200B (zh) * | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
LT3372605T (lt) | 2008-10-22 | 2022-02-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
KR102132405B1 (ko) * | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
JP5959541B2 (ja) * | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン |
BR112013029201B1 (pt) * | 2011-05-13 | 2022-08-09 | Array Biopharma Inc | Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas |
CA2858958C (en) * | 2011-12-12 | 2016-10-04 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors |
TR201808280T4 (tr) * | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pirazolo[1,5-a]pirimidin-bazlı bileşikler, bunları içeren bileşimler, ve bunların kullanım usulleri. |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
RU2664541C2 (ru) * | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
MY193524A (en) | 2014-01-24 | 2022-10-18 | Turning Point Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
JP6382997B2 (ja) * | 2014-02-07 | 2018-08-29 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
RS59286B1 (sr) | 2014-05-15 | 2019-10-31 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
RS64122B1 (sr) * | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
AU2015355220B2 (en) | 2014-12-02 | 2020-02-27 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
KR102659741B1 (ko) * | 2014-12-15 | 2024-04-23 | 주식회사 씨엠지제약 | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 |
EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AU2016270321B2 (en) * | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
TN2017000502A1 (en) * | 2015-06-01 | 2019-04-12 | Loxo Oncology Inc | Methods of diagnosing and treating cancer |
KR102599788B1 (ko) | 2015-07-02 | 2023-11-07 | 터닝 포인트 테라퓨틱스, 인크. | 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클 |
LT3319969T (lt) | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
LT3322706T (lt) | 2015-07-16 | 2021-03-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai |
JP6817287B2 (ja) | 2015-07-21 | 2021-01-20 | ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. | キラルジアリール大環状分子及びその使用 |
JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ntrk関連障害の治療に有用な化合物および組成物 |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
US10370379B2 (en) | 2015-11-19 | 2019-08-06 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
HRP20230704T1 (hr) * | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
HUE057733T2 (hu) * | 2016-10-28 | 2022-06-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Neuropátiás faktor tirozinkináz receptor inhibitorként alkalmazott amino-pirazolopirimidin vegyület |
AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
CN111182903A (zh) | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
ES2930081T3 (es) * | 2017-08-11 | 2022-12-07 | Teligene Ltd | Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
CN113735881A (zh) * | 2017-08-23 | 2021-12-03 | 正大天晴药业集团股份有限公司 | 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途 |
CN107556226B (zh) * | 2017-09-21 | 2020-06-30 | 苏州明锐医药科技有限公司 | 一种拉曲替尼中间体的制备方法 |
CN107445879B (zh) * | 2017-09-21 | 2020-07-24 | 苏州立新制药有限公司 | 拉曲替尼中间体的制备方法 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
US11339164B2 (en) | 2017-10-31 | 2022-05-24 | Assia Chemical Industries Ltd. | Crystalline form E1 of larotrectinib ethanesulfonate |
AU2018364938B2 (en) * | 2017-11-10 | 2021-11-11 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
CN107987082B (zh) * | 2017-11-14 | 2019-09-20 | 苏州东南药业股份有限公司 | 一种Larotrectinib的制备方法及其中间体 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
ES2908773T3 (es) | 2017-12-15 | 2022-05-03 | Pyramid Biosciences Inc | Derivados de 5-(2-(2,5-difluorofenil)pirrolidin-1-il)-3-(1H-pirazol-1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de Trk quinasa para el tratamiento del cáncer |
EP4151641A1 (en) | 2017-12-19 | 2023-03-22 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating cancer |
WO2019120194A1 (zh) * | 2017-12-22 | 2019-06-27 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
CN109575025B (zh) | 2018-01-23 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
TW201932472A (zh) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
JP7294677B2 (ja) * | 2018-03-14 | 2023-06-20 | フォチョン・ファーマシューティカルズ・リミテッド | TRKキナーゼ阻害剤としての置換(2-アザビシクロ[3.1.0]ヘキサン-2-イル)ピラゾロ[1,5-a]ピリミジン化合物及び置換(2-アザビシクロ[3.1.0]ヘキサン-2-イル)イミダゾ[1,2-b]ピリダジン化合物 |
CN110305138B (zh) * | 2018-03-27 | 2021-04-23 | 海创药业股份有限公司 | 一种治疗癌症的化合物及其用途 |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
WO2019189888A1 (ja) | 2018-03-30 | 2019-10-03 | 住友重機械工業株式会社 | 建設機械の運転支援システム、建設機械 |
JP7128345B2 (ja) | 2018-04-25 | 2022-08-30 | プライムジーン(ベイジン)カンパニー リミテッド | ジアリール大員環化合物、医薬組成物及びその用途 |
CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
CN110627812B (zh) * | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
AU2019314302A1 (en) | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
CA3109104A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Fluoro .beta.-carboline compounds |
WO2020037004A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Pyrrolo - dipyridine compounds |
CN110857304B (zh) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk抑制剂、其制备方法和用途 |
JP7443373B2 (ja) | 2018-09-03 | 2024-03-05 | タイリガンド バイオサイエンス(シャンハイ)リミテッド | 抗がん性薬物としてのtrk阻害剤 |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
EP3858834A4 (en) * | 2018-09-29 | 2022-06-22 | Shandong Luye Pharmaceutical Co., Ltd. | PYRAZOLOPYRIMIDE DERIVATIVES AS SELECTIVE TRK INHIBITORS |
CN111039947A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
CN111171020A (zh) | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
CN109232582B (zh) * | 2018-11-28 | 2021-02-05 | 安礼特(上海)医药科技有限公司 | 拉洛替尼硫酸氢盐晶型及其制备和应用 |
CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
CN109608464B (zh) * | 2018-12-12 | 2021-09-24 | 上海健康医学院 | 一种放射性碘标记Larotrectinib化合物及其制备方法和应用 |
CN109705124B (zh) * | 2018-12-14 | 2021-09-24 | 上海健康医学院 | 一种放射性氟标记Larotrectinib化合物及其制备方法 |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
CN111362946A (zh) * | 2018-12-25 | 2020-07-03 | 上海度德医药科技有限公司 | 一种药物化合物及其组合物和应用 |
CN109942574B (zh) * | 2019-01-11 | 2022-04-01 | 成都阿奇生物医药科技有限公司 | 天奇替尼及其制备方法和用途 |
CN109942582B (zh) * | 2019-03-15 | 2020-12-01 | 上海健康医学院 | 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用 |
AU2020242735B2 (en) | 2019-03-19 | 2022-12-01 | Central China Normal University | Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
US20200398978A1 (en) * | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
WO2021023858A1 (en) * | 2019-08-08 | 2021-02-11 | Université De Strasbourg | TrkB POSITIVE ALLOSTERIC MODULATORS |
CN110804059B (zh) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | 氨基甲酸酯类化合物、药物组合物及其应用 |
CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN112812118A (zh) * | 2019-11-18 | 2021-05-18 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业(成都)有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021187878A1 (ko) * | 2020-03-17 | 2021-09-23 | 제이투에이치바이오텍 주식회사 | 변이성 trk 융합 단백질 억제용 화합물, 이의 의약 용도 및 제조 방법 |
CN113563343B (zh) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | 取代的吡唑并[1,5-a]嘧啶化合物及其用途 |
WO2022168115A1 (en) | 2021-02-05 | 2022-08-11 | Mylan Laboratories Limited | A process for the preparation of larotrectinib or its salts |
WO2023083357A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
CN116003469B (zh) * | 2022-03-23 | 2023-10-17 | 南京知和医药科技有限公司 | 嘧啶基抗病毒化合物的制备与使用方法 |
CN114907315B (zh) * | 2022-05-17 | 2023-09-12 | 重庆医科大学 | Selitrectinib中间体的合成方法 |
CN117343064B (zh) * | 2022-07-05 | 2024-04-16 | 南京知和医药科技有限公司 | 一种具有抗病毒作用的嘧啶衍生物的制备与应用 |
WO2024023836A1 (en) | 2022-07-27 | 2024-02-01 | Mylan Laboratories Limited | Polymorphic form of larotrectinib sulfate |
EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1017286A (en) | 1909-03-01 | 1912-02-13 | Du Pont Powder Co | Apparatus for treating explosive powder. |
US1001160A (en) | 1910-04-05 | 1911-08-22 | Paul A Otto | Aerodrome. |
US1004709A (en) | 1910-05-20 | 1911-10-03 | Albert E Yerkes | Spraying device. |
US1013712A (en) | 1911-06-03 | 1912-01-02 | Alfred D Williams | Tie and rail-fastener. |
NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
ATE212985T1 (de) | 1993-11-30 | 2002-02-15 | Searle & Co | Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
JPH1020683A (ja) | 1996-07-05 | 1998-01-23 | Fuji Xerox Co Ltd | 画像形成装置 |
JP3898296B2 (ja) * | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
EP0979231B1 (en) | 1997-04-25 | 2004-11-24 | Takeda Chemical Industries, Ltd. | Condensed pyridazine derivatives, their production and use |
TR200102109T2 (tr) | 1999-01-21 | 2001-12-21 | Bristol-Myers Squibb Company | Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
KR100823764B1 (ko) | 2000-06-22 | 2008-04-21 | 제넨테크, 인크. | 아고니스트 안티-티알케이-씨 모노클로날 항체 |
GB0028575D0 (en) | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
BR0116388A (pt) | 2000-12-22 | 2003-09-30 | Astrazeneca Ab | Composto, processo para preparar um composto, composição farmacêutica e método para tratar, em um animal de sangue quente, distúrbios de alimentação e uso de um composto |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
CN101653604A (zh) | 2001-05-30 | 2010-02-24 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
GB0207249D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
US7449488B2 (en) * | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
JP4024624B2 (ja) | 2002-08-26 | 2007-12-19 | 富士通株式会社 | 半導体装置の製造方法及び製造装置 |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
EP1537116B1 (en) * | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
AU2003298942A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US20070037150A1 (en) | 2003-02-21 | 2007-02-15 | The Johns Hopkins University | Tyrosine kinome |
JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
CN1795206A (zh) | 2003-04-28 | 2006-06-28 | 株式会社嘉尔药物 | 半乳糖凝集素-9诱导因子 |
JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
EA009517B1 (ru) * | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Пиразолопиримидины |
EA013614B1 (ru) | 2003-07-15 | 2010-06-30 | Амджен Инк. | Изолированное антитело к фактору роста нервов (ngf) и способы его применения |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
UA83881C2 (en) | 2003-12-18 | 2008-08-26 | Янссен Фармацевтика Н.В. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
UA91677C2 (ru) | 2004-03-30 | 2010-08-25 | Интермюн, Инк. | Макроциклические соединения как ингибиторы вирусной репликации |
JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
MX2007009842A (es) * | 2005-02-16 | 2007-08-23 | Astrazeneca Ab | Compuestos quimicos. |
CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
SI1869049T1 (sl) | 2005-03-21 | 2009-08-31 | Lilly Co Eli | Spojine imidazopiridazina |
EP1877057A1 (en) | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
KR20080015409A (ko) | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
CN100406650C (zh) | 2005-06-05 | 2008-07-30 | 徐斌 | 一种抗特大变位的模块式梳型桥梁伸缩缝装置 |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
BRPI0613962A2 (pt) | 2005-07-25 | 2009-03-24 | Intermune Inc | inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
CN101232871A (zh) | 2005-08-03 | 2008-07-30 | 伊士曼化工公司 | 生育酚聚乙二醇琥珀酸酯粉末及其制备方法 |
US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
WO2007024680A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
PT1919979E (pt) | 2005-08-25 | 2014-03-07 | Creabilis Therapeutics Spa | Polímeros conjugados de k-252a e seus derivados |
DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CA2624500A1 (en) * | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
TWI421078B (zh) * | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
GEP20104956B (en) | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
JP5030961B2 (ja) | 2005-10-11 | 2012-09-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク | 細胞のアポトーシスの検出および定量化用の化合物およびキット |
US8101625B2 (en) | 2005-10-21 | 2012-01-24 | Exelixis, Inc. | Pyrimidinones as Casein Kinase II (CK2) modulators |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
US20070166336A1 (en) | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
US20080108611A1 (en) | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
WO2007102679A1 (en) | 2006-03-06 | 2007-09-13 | Je Il Pharmaceutical Co., Ltd. | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
EP2001880A2 (en) | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Heterobicyclic pyrazole compounds and methods of use |
GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
US7781433B2 (en) | 2006-04-26 | 2010-08-24 | Piramed Limited | Pharmaceutical compounds |
EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
TWI419889B (zh) | 2006-07-05 | 2013-12-21 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔1,5-a〕嘧啶化合物 |
US8044049B2 (en) | 2006-08-04 | 2011-10-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US20100029619A1 (en) * | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
WO2008030579A2 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
US20090286779A1 (en) * | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
AU2007316417B2 (en) | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
US7820684B2 (en) | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
CN101801972A (zh) * | 2007-03-28 | 2010-08-11 | 英诺瓦西亚公司 | 作为硬脂酰-辅酶a去饱和酶抑制剂的吡唑并[1,5-a]嘧啶 |
WO2008124323A1 (en) | 2007-04-03 | 2008-10-16 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
EP2152688A1 (en) | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
WO2008155421A2 (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
PL2176231T3 (pl) | 2007-07-20 | 2017-04-28 | Nerviano Medical Sciences S.R.L. | Podstawione pochodne indazolu aktywne jako inhibitory kinazy |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CA2695997C (en) | 2007-08-10 | 2016-11-22 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
CA2702838A1 (en) | 2007-10-16 | 2009-04-23 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
JP2011501760A (ja) | 2007-10-23 | 2011-01-13 | ノバルティス アーゲー | 呼吸器疾患の処置のためのtrkb抗体の使用 |
WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
MX2010005950A (es) | 2007-11-28 | 2010-06-17 | Schering Corp | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CN102015769B (zh) | 2008-01-17 | 2014-12-10 | Irm责任有限公司 | 改进的抗-trkb抗体 |
JP2011513360A (ja) | 2008-03-03 | 2011-04-28 | ユセベ ファルマ ソシエテ アノニム | 医薬溶液、調製方法及び治療的使用 |
KR100963051B1 (ko) | 2008-03-14 | 2010-06-09 | 광동제약 주식회사 | 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물 |
US20090275622A1 (en) | 2008-04-30 | 2009-11-05 | Prasoona Linga | Nizatidine formulations |
US8507488B2 (en) * | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
JP5677296B2 (ja) | 2008-07-29 | 2015-02-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | グリオーマの治療のためのcdk阻害剤の使用 |
CN103965200B (zh) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
LT3372605T (lt) | 2008-10-22 | 2022-02-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai |
BRPI0914404A2 (pt) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
WO2010058006A1 (en) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
ES2637174T3 (es) | 2009-02-12 | 2017-10-11 | Cell Signaling Technology, Inc. | Expresión de ROS mutante en el cáncer de hígado humano |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP3305073B1 (en) | 2009-12-21 | 2019-05-15 | Samumed, LLC | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2011101408A1 (en) | 2010-02-18 | 2011-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for preventing cancer metastasis |
JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
EA028080B1 (ru) | 2010-06-09 | 2017-10-31 | Дана-Фарбер Кэнсер Инститьют, Инк. | Мутация в mek1, придающая устойчивость к ингибиторам raf и mek |
LT3333188T (lt) | 2010-08-19 | 2022-06-10 | Zoetis Belgium S.A. | Anti-ngf antikūnai ir jų panaudojimas |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン |
BR112013029201B1 (pt) | 2011-05-13 | 2022-08-09 | Array Biopharma Inc | Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
EP2779833A4 (en) | 2011-11-14 | 2015-03-18 | Tesaro Inc | MODULATION OF SPECIFIC TYROSINE KINASES |
CA2858958C (en) | 2011-12-12 | 2016-10-04 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors |
JP6160613B2 (ja) | 2012-04-26 | 2017-07-12 | 小野薬品工業株式会社 | Trk阻害化合物 |
NZ703124A (en) | 2012-05-23 | 2016-07-29 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
NZ702930A (en) | 2012-06-28 | 2017-05-26 | Mcneil-Ppc Inc | Racecadotril liquid compositions |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
US20150218652A1 (en) | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
JP2014082984A (ja) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | 新規ntrk2活性化変異の検出法 |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
BR112015002626A2 (pt) | 2012-11-29 | 2017-09-26 | Yeda Res & Dev | métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
SG11201506514QA (en) | 2013-02-19 | 2015-09-29 | Ono Pharmaceutical Co | Trk-INHIBITING COMPOUND |
US20160010068A1 (en) | 2013-02-22 | 2016-01-14 | Boris C. Bastian | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
WO2014134096A1 (en) | 2013-02-27 | 2014-09-04 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
ES2900301T3 (es) | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
CN113337604A (zh) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
JP2016515508A (ja) | 2013-03-15 | 2016-05-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 融合タンパク質及びその方法 |
WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
WO2014172046A2 (en) | 2013-04-17 | 2014-10-23 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
WO2015003658A1 (en) | 2013-07-11 | 2015-01-15 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
JP6534930B2 (ja) | 2013-07-26 | 2019-06-26 | 公益財団法人がん研究会 | Ntrk3融合体の検出法 |
US10407509B2 (en) | 2013-07-30 | 2019-09-10 | Blueprint Medicines Corporation | NTRK2 fusions |
EP3060207A4 (en) | 2013-10-24 | 2017-04-12 | Georgetown University | Methods and compositions for treating cancer |
WO2015064621A1 (ja) | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
MY193524A (en) | 2014-01-24 | 2022-10-18 | Turning Point Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
JP6197125B2 (ja) | 2014-02-05 | 2017-09-13 | ブイエム オンコロジー リミテッド ライアビリティ カンパニー | 化合物の組成物およびその使用 |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
RS59286B1 (sr) | 2014-05-15 | 2019-10-31 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze |
WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
US20170114415A1 (en) | 2014-05-30 | 2017-04-27 | The Regents Of The University Of Colorado, A Body Corporate | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
WO2016019341A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
CN110655502A (zh) | 2014-08-18 | 2020-01-07 | 小野药品工业株式会社 | 抑制Trk的化合物的酸加成盐 |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
RS64122B1 (sr) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
KR102659741B1 (ko) | 2014-12-15 | 2024-04-23 | 주식회사 씨엠지제약 | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 |
CN104672121B (zh) | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法 |
MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
AU2016270321B2 (en) | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
TN2017000502A1 (en) | 2015-06-01 | 2019-04-12 | Loxo Oncology Inc | Methods of diagnosing and treating cancer |
US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
KR102599788B1 (ko) | 2015-07-02 | 2023-11-07 | 터닝 포인트 테라퓨틱스, 인크. | 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클 |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
WO2017127835A2 (en) | 2016-01-22 | 2017-07-27 | The Medicines Company | Aqueous formulations and methods of preparation and use thereof |
JPWO2017155018A1 (ja) | 2016-03-11 | 2019-01-17 | 小野薬品工業株式会社 | Trk阻害剤抵抗性の癌治療剤 |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
MA44733A (fr) | 2016-04-19 | 2019-02-27 | Exelixis Inc | Procédé de traitement du cancer du sein négatif triple |
WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
HRP20230704T1 (hr) | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
-
2009
- 2009-10-21 LT LTEP18151233.6T patent/LT3372605T/lt unknown
- 2009-10-21 DK DK16166461.0T patent/DK3106463T6/da active
- 2009-10-21 EP EP13197815.7A patent/EP2725028B1/en active Active
- 2009-10-21 PL PL16166461T patent/PL3106463T6/pl unknown
- 2009-10-21 ES ES13197815.7T patent/ES2588504T3/es active Active
- 2009-10-21 TW TW105143120A patent/TWI639605B/zh active
- 2009-10-21 ME MEP-2018-133A patent/ME03010B/me unknown
- 2009-10-21 KR KR1020147029018A patent/KR101652189B1/ko active IP Right Grant
- 2009-10-21 HU HUE18151233A patent/HUE057625T2/hu unknown
- 2009-10-21 SG SG2014004790A patent/SG196855A1/en unknown
- 2009-10-21 EP EP18151233.6A patent/EP3372605B1/en active Active
- 2009-10-21 PT PT161664610T patent/PT3106463T/pt unknown
- 2009-10-21 SG SG10201900514RA patent/SG10201900514RA/en unknown
- 2009-10-21 RS RS20211578A patent/RS62869B1/sr unknown
- 2009-10-21 EP EP09740245.7A patent/EP2350071B1/en active Active
- 2009-10-21 PT PT181512336T patent/PT3372605T/pt unknown
- 2009-10-21 PT PT97402457T patent/PT2350071E/pt unknown
- 2009-10-21 SI SI200931843T patent/SI3106463T1/en unknown
- 2009-10-21 EP EP16166461.0A patent/EP3106463B3/en active Active
- 2009-10-21 ES ES16166461T patent/ES2669581T7/es active Active
- 2009-10-21 KR KR1020187011433A patent/KR102037619B1/ko active IP Right Grant
- 2009-10-21 LT LTEP16166461.0T patent/LT3106463T/lt unknown
- 2009-10-21 ES ES09740245.7T patent/ES2456346T3/es active Active
- 2009-10-21 US US13/125,263 patent/US8513263B2/en active Active
- 2009-10-21 UY UY0001032192A patent/UY32192A/es active IP Right Grant
- 2009-10-21 LT LTEP13197815.7T patent/LT2725028T/lt unknown
- 2009-10-21 KR KR1020167022867A patent/KR101784798B1/ko active Protection Beyond IP Right Term
- 2009-10-21 BR BRPI0919873A patent/BRPI0919873B8/pt active IP Right Grant
- 2009-10-21 SG SG10201914059WA patent/SG10201914059WA/en unknown
- 2009-10-21 PL PL18151233T patent/PL3372605T3/pl unknown
- 2009-10-21 PL PL09740245T patent/PL2350071T3/pl unknown
- 2009-10-21 KR KR1020117011561A patent/KR101634833B1/ko active Protection Beyond IP Right Term
- 2009-10-21 MX MX2011004204A patent/MX2011004204A/es active IP Right Grant
- 2009-10-21 RU RU2011120345/04A patent/RU2523544C2/ru active
- 2009-10-21 CN CN2009801518250A patent/CN102264736B/zh active Active
- 2009-10-21 TW TW107124940A patent/TWI670272B/zh active
- 2009-10-21 KR KR1020177027624A patent/KR101853026B1/ko active IP Right Grant
- 2009-10-21 AR ARP090104042A patent/AR074052A1/es active IP Right Grant
- 2009-10-21 MY MYPI2011001770A patent/MY169791A/en unknown
- 2009-10-21 RS RS20180555A patent/RS57221B2/sr unknown
- 2009-10-21 PT PT131978157T patent/PT2725028T/pt unknown
- 2009-10-21 ES ES18151233T patent/ES2900243T3/es active Active
- 2009-10-21 NO NO16166461A patent/NO3106463T3/no unknown
- 2009-10-21 AU AU2009308465A patent/AU2009308465B2/en active Active
- 2009-10-21 DK DK13197815.7T patent/DK2725028T3/en active
- 2009-10-21 SI SI200930889T patent/SI2350071T1/sl unknown
- 2009-10-21 NZ NZ592809A patent/NZ592809A/xx unknown
- 2009-10-21 HR HRP20211722TT patent/HRP20211722T1/hr unknown
- 2009-10-21 CN CN201310379854.0A patent/CN103509017B/zh active Active
- 2009-10-21 RS RS20140151A patent/RS53247B/en unknown
- 2009-10-21 JP JP2011533303A patent/JP5600111B2/ja active Active
- 2009-10-21 UA UAA201106366A patent/UA106054C2/uk unknown
- 2009-10-21 HU HUE16166461A patent/HUE037716T2/hu unknown
- 2009-10-21 TW TW103132675A patent/TWI577680B/zh not_active IP Right Cessation
- 2009-10-21 TW TW098135670A patent/TWI458729B/zh active
- 2009-10-21 TR TR2018/07039T patent/TR201807039T4/tr unknown
- 2009-10-21 CA CA2741313A patent/CA2741313C/en active Active
- 2009-10-21 HU HUE13197815A patent/HUE030413T2/en unknown
- 2009-10-21 DK DK18151233.6T patent/DK3372605T3/da active
- 2009-10-21 SI SI200932152T patent/SI3372605T1/sl unknown
- 2009-10-21 WO PCT/US2009/061519 patent/WO2010048314A1/en active Application Filing
- 2009-10-21 SI SI200931507A patent/SI2725028T1/sl unknown
- 2009-10-21 PL PL13197815.7T patent/PL2725028T3/pl unknown
- 2009-10-21 DK DK09740245.7T patent/DK2350071T3/en active
-
2011
- 2011-04-14 IL IL212341A patent/IL212341A0/en unknown
- 2011-04-19 CL CL2011000880A patent/CL2011000880A1/es unknown
- 2011-05-16 CR CR20110261A patent/CR20110261A/es unknown
- 2011-05-20 CO CO11062725A patent/CO6440551A2/es active IP Right Grant
-
2012
- 2012-01-31 HK HK12100876.5A patent/HK1160640A1/xx unknown
-
2013
- 2013-07-16 US US13/943,590 patent/US8865698B2/en active Active
-
2014
- 2014-03-31 HR HRP20140309AT patent/HRP20140309T1/hr unknown
- 2014-06-30 JP JP2014134304A patent/JP5832597B2/ja not_active Expired - Fee Related
- 2014-07-02 HK HK14106634.3A patent/HK1193101A1/zh unknown
- 2014-09-18 US US14/490,460 patent/US9447104B2/en active Active
- 2014-10-21 SM SM201400153T patent/SMT201400153B/xx unknown
-
2015
- 2015-01-14 US US14/596,611 patent/US9127013B2/en active Active
- 2015-08-31 JP JP2015170033A patent/JP6105008B2/ja active Active
- 2015-09-04 US US14/846,166 patent/US9676783B2/en active Active
-
2016
- 2016-08-24 CY CY20161100831T patent/CY1118199T1/el unknown
- 2016-09-18 IL IL247884A patent/IL247884B/en active IP Right Grant
- 2016-09-20 JP JP2016182689A patent/JP6431512B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-05 US US15/399,389 patent/US10005783B2/en active Active
-
2018
- 2018-01-03 US US15/860,948 patent/US10047097B2/en active Active
- 2018-05-14 HR HRP20180746TT patent/HRP20180746T4/hr unknown
- 2018-05-18 CY CY20181100514T patent/CY1120260T1/el unknown
- 2018-07-25 US US16/044,653 patent/US10774085B2/en active Active
- 2018-08-29 RU RU2018131134A patent/RU2018131134A/ru unknown
- 2018-09-24 AR ARP180102740A patent/AR112833A2/es not_active Application Discontinuation
- 2018-11-02 JP JP2018207330A patent/JP6788649B2/ja active Active
-
2020
- 2020-03-10 LT LTPA2020504C patent/LTC3106463I2/lt unknown
- 2020-03-10 NO NO2020004C patent/NO2020004I1/no unknown
- 2020-03-10 NL NL301033C patent/NL301033I2/nl unknown
- 2020-03-11 LU LU00150C patent/LUC00150I2/fr unknown
- 2020-03-11 HU HUS2000006C patent/HUS000512I2/hu unknown
- 2020-03-16 CY CY2020006C patent/CY2020006I2/el unknown
- 2020-09-14 US US17/020,461 patent/US11267818B2/en active Active
- 2020-10-18 IL IL278119A patent/IL278119B/en unknown
-
2021
- 2021-11-26 CY CY20211101031T patent/CY1124923T1/el unknown
-
2022
- 2022-09-09 US US17/941,367 patent/US20230234955A1/en active Pending
-
2023
- 2023-03-28 US US18/191,283 patent/US20240132500A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120260T1 (el) | Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk | |
CY1115107T1 (el) | ΕΝΩΣΕΙΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΩΝ ΙΜΙΔΑΖΟ[1,2-b]ΠΥΡΙΔΑΖΙΝΩΝ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ TRK | |
CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
CY1118498T1 (el) | Παραγωγα πυριδαζινονης | |
CY1112206T1 (el) | Παραγωγα πυριδαζινονης για την θεραπεια ογκων | |
CY1111556T1 (el) | Παραγωγα 2-βενζυλοπυριδαζινονης ως αναστολεις μετ-κινασης | |
CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
CY1118717T1 (el) | Αναστολεις c-fms κινασης | |
CY1114574T1 (el) | Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων | |
CY1117546T1 (el) | Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
CY1113443T1 (el) | Παραγωγα πυριδαζινονης | |
NO20082598L (no) | ERBB-inhibitorer | |
BRPI0818543A2 (pt) | inibidores de proteína cinase | |
UY29246A1 (es) | Nuevos compuestos | |
DK1761520T3 (da) | Kinaseinhibitorer | |
GT200600143A (es) | Fenilacetamidas apropiadas como inhibidores de la proteina kinasa | |
DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
MX364157B (es) | Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa. | |
EA200901601A1 (ru) | Производные пиридазинона | |
DOP2005000010A (es) | Inhibidores de quinasa | |
CY1112235T1 (el) | Παραγωγα 3,6-διυδρο-2-οξο-6η-(1,3,4)-θειαδιαζινης | |
EA200801430A1 (ru) | Производные триазола | |
CY1113698T1 (el) | Παραγωγα πυριδαζινονης |